Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study.

Cancers (Basel) · 2023 · PMC10001327 · PMID 36900217

Europe PMC DOI

hedged sentence

0.1160

closest p · 2.3× alpha

0.1160

boldest claim

The sentences

showed a trendp = 0.116not close (p > 0.1)

Patients with progression to the first treatment showed a trend towards shorter PFS, which was not statistically significant (4.5 months [95% CI: 2.4–6.6 months] vs. 7 months [95% CI: 1.6–12.4 months], p = 0.116).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.